Zai Lab reported second quarter 2026 revenue of US$106.31 million and a net loss of US$50.83 million, with losses wider than a year earlier. The earnings release appeared to shift short-term sentiment, as the stock posted an 11.69% one-day return and a 27.64% seven-day return, though the one-year total shareholder return remains down 33.30%. A widely followed fair value estimate places the stock at $33.30, suggesting it is about 30% undervalued relative to its last closing price of $23.32, while a separate discounted cash flow model points to a fair value of $91.16. The bullish narrative hinges on multiple high-potential product launches and label expansions over the next 12 to 18 months, combined with a deep oncology and immunology pipeline, which are expected to significantly increase the addressable market and diversify revenue streams.
Zai Lab LtdQ2 revenue and wider net loss reported; stock rose despite losses, with fair value estimates suggesting undervaluation.
